Genmab revenue and financials
Secondary listing. The primary listing is Genmab · Nasdaq Copenhagen (DKK)
$37.80Change from previous close: −1.77%Absolute change: −$0.68
In the fiscal year ended December 2025, Genmab reported revenue of kr 3.72B (+19.19% year over year). Net income was kr 963M, a net margin of 25.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +19.19%
- 2025 vs 2024
- Net income growth
- −87.72%
- 2025 vs 2024
- Net margin
- 25.9%
- 2024: 251.3%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1,186 | 1,126 | 7,380 | 1,326 | 1,015 | 1,589 |
| Depreciation and amortization | 57.0 | 52.0 | 43.0 | 40.0 | 28.0 | 12.0 |
| Capital expenditure | -37.0 | -27.0 | -53.0 | -79.0 | -72.0 | -89.0 |
| Investing cash flow | -5,643 | -1,447 | -185 | — | — | — |
| Financing cash flow | 4,789 | -566 | -89.0 | — | — | — |
| Share repurchases | -448 | -576 | -81.0 | — | — | — |
| Debt repaid | -13.0 | -9.0 | -14.0 | — | — | — |
| Effect of exchange rates | 3.0 | 63.0 | -12.0 | — | — | — |
| Net change in cash | 335 | -824 | 797 | — | — | — |
| Free cash flow | 1,149 | 1,099 | 1,017 | — | — | — |
| Levered free cash flow | 1,068 | 915 | — | — | — | — |